NextCure, Inc.
NXTC · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $41,488 | $47,931 | $54,199 | $50,192 |
| G&A Expenses | $15,718 | $19,706 | $21,710 | $20,573 |
| SG&A Expenses | $15,718 | $19,706 | $21,710 | $20,573 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $2,542 | $0 | $0 | $0 |
| Operating Expenses | $59,748 | $67,637 | $75,909 | $70,765 |
| Operating Income | -$59,748 | -$67,637 | -$75,909 | -$70,765 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $4,094 | $4,914 | $1,176 | $1,376 |
| Pre-Tax Income | -$55,654 | -$62,723 | -$74,733 | -$69,389 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$55,654 | -$62,723 | -$74,733 | -$69,389 |
| % Margin | – | – | – | – |
| EPS | -23.88 | -27.039 | -32.324 | -30.152 |
| % Growth | 11.7% | 16.3% | -7.2% | – |
| EPS Diluted | -23.88 | -27.039 | -32.324 | -30.152 |
| Weighted Avg Shares Out | 2,330 | 2,320 | 2,312 | 2,301 |
| Weighted Avg Shares Out Dil | 2,330 | 2,320 | 2,312 | 2,301 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $1,167 | $1 |
| Interest Expense | $0 | $0 | $0 | $77 |
| Depreciation & Amortization | $2,865 | $3,684 | $4,124 | $4,177 |
| EBITDA | -$54,341 | -$63,953 | -$71,785 | -$66,588 |
| % Margin | – | – | – | – |